Invention Grant
- Patent Title: Inhibition of autism spectrum disorder using ribosomal read-through compounds
-
Application No.: US16647591Application Date: 2018-09-17
-
Publication No.: US11213537B2Publication Date: 2022-01-04
- Inventor: Marc Buehler , Veronica Ostapcuk
- Applicant: Friedrich Miescher Institute for Biomedical Research
- Applicant Address: CH Basel
- Assignee: Friedrich Miescher Institute for Biomedical Research
- Current Assignee: Friedrich Miescher Institute for Biomedical Research
- Current Assignee Address: CH Basel
- Agency: Hoxie & Associates LLC
- Priority: EP17191642 20170918
- International Application: PCT/IB2018/057095 WO 20180917
- International Announcement: WO2019/053667 WO 20190321
- Main IPC: A61K31/7036
- IPC: A61K31/7036 ; A61K31/165 ; A61K31/4245 ; A61K31/5377 ; A61K31/7048
Abstract:
The present invention relates to the novel use of read-through compounds for use in the treatment and/or prevention of Autism Spectrum Disorder.
Public/Granted literature
- US20200261484A1 INHIBITION OF AUTISM SPECTRUM DISORDER USING RIBOSOMAL READ-THROUGH COMPOUNDS Public/Granted day:2020-08-20
Information query
IPC分类:
